Kerala State Drug Formulary.pdf

Hormones and other endocrine drugs
P/C: Use with caution in children.
A/E: Constipation, diarrhoea, dryness of mouth, increased
thirst and urination, loss of appetite, nausea, vomiting,
lethargy, itching,irregular heartbeat, muscle pain and
pancreatitis.
P/A: Tablet 125 mcg, 200 mcg, 400 mcg.
Capsule 125 mcg.
Solution 200 mcg/mL.
Dose: Adult : 0.25 to 0.5 mg/day
D/ I: Increased potential for toxicity with other Vitamin D
analogues;hyperphosphatemia with phosphorous
containing preparations;hypercalcemia due to the drug
potentiates digitalis toxicity; reduced absorption of
drug by mineral oil, cholestyramine or colestipol;
increased risk of hypercalcemia with thiazide diuretics;
antagonises calcitonin, etidronate or plicamycin in the
treatment of hypercalcemia; hydantoin, barbiturates
or primidone accelerates metabolism of drug by hepatic
microsomal drug induction.
1,25 dihydroxy Cholecaliceferol (Calcitriol)
I : Hypocalcemia of malabsorption, CRF and
hypoparathyrodism.
Dose : Hypocalcemia : Adult : 0.25 - 2.0 mcg/ day, oral.
BISPHOSPHONATES
These are groups of drugs which inhibit calcium mobilization from
bone. It includes etidronate and alendronate.
Sodium Etidronate
I: Hypercalcemia of malignancy, Paget’s disease of bone.
C/I: Hypersensitivity, pregnancy, hypercalcemia, cardiac
failure,enterocolitis,hyperphosphatemia, hypocalcemia
or hypovitaminosis D, impaired renal function.
P/C: Careful monitoring of fluid.and electrolyte status in
elderly since they are more prone to over hydration
with etidronate. Use with caution in children.
A/E: Bone pain or tenderness, osteomalacia, diarrhoea,
nausea, urticaria.
P/A: Tablet 200 mg, 400 mg.
Injection 50 mg/ mL.
256